Richard F. Pops is a prominent figure in the biopharmaceutical industry, currently serving as the Chairman and Chief Executive Officer at Alkermes, a position he has held since 1991. Under his leadership, Alkermes has grown from a small start-up into a global biopharmaceutical company focused on developing innovative medicines for patients with serious chronic diseases. Pops has been instrumental in steering the company through its transformation, guiding it through numerous successful product developments and strategic partnerships. Before joining Alkermes, Pops held various roles in the healthcare sector, which provided him with a solid foundation in the industry. He started his career at a medical device company, where he honed his skills in product development and business strategy. His experience in these areas has been crucial in his role at Alkermes, where he has overseen the development and commercialization of several key products, including treatments for schizophrenia, addiction, and multiple sclerosis. Pops's leadership has been recognized with numerous awards, including being named one of the "100 Most Influential People in Biotechnology" by Scientific American Worldview. As CEO, Pops continues to drive Alkermes's mission to develop life-changing medicines. He is actively involved in shaping the company's research and development strategy, ensuring that it remains at the forefront of innovation in the biopharmaceutical field. His dedication to improving patient outcomes and his strategic vision have cemented his reputation as a respected leader in the industry. Under his guidance, Alkermes remains committed to advancing its pipeline of novel therapies and expanding its global reach.